PortfoliosLab logoPortfoliosLab logo
BIB vs. LABU
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

BIB vs. LABU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ProShares Ultra Nasdaq Biotechnology (BIB) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BIB achieves a 12.50% return, which is significantly lower than LABU's 47.57% return. Over the past 10 years, BIB has outperformed LABU with an annualized return of 9.71%, while LABU has yielded a comparatively lower -7.18% annualized return.


BIB

1D
1.97%
1M
9.49%
YTD
12.50%
6M
8.62%
1Y
100.86%
3Y*
19.65%
5Y*
-0.74%
10Y*
9.71%

LABU

1D
2.26%
1M
34.26%
YTD
47.57%
6M
36.98%
1Y
324.35%
3Y*
23.36%
5Y*
-31.01%
10Y*
-7.18%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BIB vs. LABU - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
BIB
ProShares Ultra Nasdaq Biotechnology
12.50%59.21%-9.84%-1.06%-28.85%-6.02%39.79%46.71%-24.93%40.49%
LABU
Direxion Daily S&P Biotech Bull 3x Shares
47.57%79.17%-26.02%-13.41%-80.36%-64.15%74.66%75.50%-57.61%149.12%

Correlation

The correlation between BIB and LABU is 0.93, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.93

Correlation (3Y)
Calculated over the trailing 3-year period

0.92

Correlation (5Y)
Calculated over the trailing 5-year period

0.91

Correlation (10Y)
Calculated over the trailing 10-year period

0.92

Correlation (All Time)
Calculated using the full available price history since May 28, 2015

0.92

The correlation between BIB and LABU has been stable across timeframes, ranging from 0.91 to 0.93 - a consistent structural relationship.

BIB vs. LABU - Sectors Allocation Comparison


Sectors
BIB
LABU

Healthcare

62.9%
99.7%

Financial Services

6.8%
0.3%

Basic Materials

-

0.0%

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

BIB
62.9%
LABU
99.7%

Financial Services

BIB
6.8%
LABU
0.3%

Basic Materials

BIB

-

LABU
0.0%

Communication Services

BIB

-

LABU

-

Consumer Cyclical

BIB

-

LABU

-

Consumer Defensive

BIB

-

LABU

-

Energy

BIB

-

LABU

-

Industrials

BIB

-

LABU

-

Real Estate

BIB

-

LABU

-

Technology

BIB

-

LABU

-

Utilities

BIB

-

LABU

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BIB vs. LABU — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BIB
BIB Risk / Return Rank: 8080
Overall Rank
BIB Sharpe Ratio Rank: 8383
Sharpe Ratio Rank
BIB Sortino Ratio Rank: 7373
Sortino Ratio Rank
BIB Omega Ratio Rank: 6565
Omega Ratio Rank
BIB Calmar Ratio Rank: 9292
Calmar Ratio Rank
BIB Martin Ratio Rank: 8888
Martin Ratio Rank

LABU
LABU Risk / Return Rank: 9191
Overall Rank
LABU Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
LABU Sortino Ratio Rank: 8686
Sortino Ratio Rank
LABU Omega Ratio Rank: 7878
Omega Ratio Rank
LABU Calmar Ratio Rank: 9797
Calmar Ratio Rank
LABU Martin Ratio Rank: 9595
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BIB vs. LABU - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BIBLABUDifference
Sharpe ratioReturn per unit of total volatility

-1.64

Sortino ratioReturn per unit of downside risk

-0.59

Omega ratioGain probability vs. loss probability

1.36

1.44

-0.08

Calmar ratioReturn relative to maximum drawdown

5.99

10.64

-4.65

Martin ratioReturn relative to average drawdown

18.30

29.90

-11.60

BIB vs. LABU - Sharpe Ratio Comparison

The current BIB Sharpe Ratio is 2.51, which is lower than the LABU Sharpe Ratio of 4.15. The chart below compares the historical Sharpe Ratios of BIB and LABU, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BIB vs. LABU - Drawdown Comparison

The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum LABU drawdown of -99.18%. Use the drawdown chart below to compare losses from any high point for BIB and LABU.


Loading charts...

Drawdown Indicators


BIBLABUDifference

Max Drawdown

Largest peak-to-trough decline

-67.24%

-99.18%

+31.94%

Max Drawdown (1Y)

Largest decline over 1 year

-16.92%

-30.70%

+13.78%

Max Drawdown (3Y)

Largest decline over 3 years

-45.30%

-78.30%

+33.00%

Max Drawdown (5Y)

Largest decline over 5 years

-65.86%

-97.59%

+31.73%

Max Drawdown (10Y)

Largest decline over 10 years

-66.20%

-98.96%

+32.76%

Current Drawdown

Current decline from peak

-17.29%

-94.80%

+77.51%

Average Drawdown

Average peak-to-trough decline

-32.71%

-81.72%

+49.01%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.53%

10.91%

-5.38%

Volatility

BIB vs. LABU - Volatility Comparison

The current volatility for ProShares Ultra Nasdaq Biotechnology (BIB) is 13.56%, while Direxion Daily S&P Biotech Bull 3x Shares (LABU) has a volatility of 29.76%. This indicates that BIB experiences smaller price fluctuations and is considered to be less risky than LABU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BIBLABUDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.56%

29.76%

-16.20%

Volatility (6M)

Calculated over the trailing 6-month period

31.65%

63.07%

-31.42%

Volatility (1Y)

Calculated over the trailing 1-year period

40.43%

78.78%

-38.35%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

43.60%

95.94%

-52.34%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

46.39%

95.44%

-49.05%

BIB vs. LABU - Expense Ratio Comparison

BIB has a 0.95% expense ratio, which is lower than LABU's 1.12% expense ratio.


Dividends

BIB vs. LABU - Dividend Comparison

BIB's dividend yield for the trailing twelve months is around 0.55%, more than LABU's 0.52% yield.


PositionTTM202520242023202220212020201920182017
BIB
ProShares Ultra Nasdaq Biotechnology
0.55%0.77%1.69%0.07%0.03%0.00%0.00%0.00%0.00%0.00%
LABU
Direxion Daily S&P Biotech Bull 3x Shares
0.52%0.84%0.35%0.35%0.00%0.00%0.00%0.28%0.64%0.17%

Frequently Asked Questions


With a correlation of 0.93, BIB and LABU move almost identically. Holding both adds very little diversification - you're essentially doubling your position in the same market segment. Choosing one is usually more capital-efficient.

LABU has higher volatility (29.76%) compared to BIB (13.56%). In terms of maximum drawdown, BIB dropped -67.24% vs LABU's -99.18%.

On 10-year performance, BIB leads with 9.71% vs -7.18% for LABU. On fees, BIB is cheaper at 0.95% per year. On volatility, BIB has been the lower-risk option at 13.56%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 10-year period, BIB has performed better with a 9.71% return vs -7.18%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

BIB is cheaper with a 0.95% expense ratio, compared with 1.12% for LABU.

BIB has the higher dividend yield at 0.55%, compared with 0.52% for LABU.

BIB tracks NASDAQ Biotechnology Index (200%), while LABU tracks S&P Biotechnology Select Industry Index (300%). They also come from different issuers: ProShares and Direxion. Their fees differ too: 0.95% for BIB and 1.12% for LABU.

LABU currently has the higher Sharpe Ratio (4.15 vs 2.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BIB and LABU

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer